Mixed feelings.Lot's of 'we are bullish' statements, but very...

Mixed feelings.

Lot's of 'we are bullish' statements, but very scant on actual expectations of FY 2025 figures.

Probably the most important takeaways for me:

No current purchasers of Febridex in Australia

Good expansion of Febridex into the USA Student health market

Progress made on CLIA waiver

Progress made on re-imbursement coding - why that wasn't done before launch is baffling tbh.

I think it all depends on the Febridex uptake in the next FY (obviously) to see whether we will be 100% reliant on IP deals to keep the doors open.

If it takes off - so will the SP. It's that simple.

Overall - 6.5/10

Lots of bones, not too much meat.